Colleen Kusy
Stock Analyst at Baird
(1.81)
# 3,335
Out of 5,090 analysts
53
Total ratings
36.96%
Success rate
-9.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $107.05 | +47.60% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $39.36 | -13.62% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $22.05 | +135.88% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $12.44 | +92.93% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $1.72 | +423.26% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $21.55 | +141.36% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.08 | +47.06% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.58 | +109.45% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.23 | +387.80% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $33.55 | +93.74% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $100 → $75 | $27.42 | +173.52% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $11.41 | +119.11% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $5.89 | +3,465.37% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.22 | +1,431.53% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.80 | +5,952.63% | 1 | Nov 2, 2021 |
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $107.05
Upside: +47.60%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $39.36
Upside: -13.62%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $22.05
Upside: +135.88%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $12.44
Upside: +92.93%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $1.72
Upside: +423.26%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $21.55
Upside: +141.36%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.08
Upside: +47.06%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.58
Upside: +109.45%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.23
Upside: +387.80%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $33.55
Upside: +93.74%
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $27.42
Upside: +173.52%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.41
Upside: +119.11%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $5.89
Upside: +3,465.37%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.22
Upside: +1,431.53%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.80
Upside: +5,952.63%